Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoIntercal: Gefitinib + Chemo Induction in EGFR+ NSCLC
NCT02326285Phase 3Terminated
- Sponsor
- AIO-Studien
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Started Nov 2015; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02326285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326285.